National Trends in Recurrent AMI Hospitalizations 1 Year After Acute Myocardial Infarction in Medicare Beneficiaries: 1999–2010

Background There are few data characterizing temporal changes in hospitalization for recurrent acute myocardial infarction (AMI) after AMI. Methods and Results Using a national sample of 2 305 441 Medicare beneficiaries hospitalized for AMI from 1999 to 2010, we evaluated changes in the incidence of 1‐year recurrent AMI hospitalization and mortality using Cox proportional hazards models. The observed recurrent AMI hospitalization rate declined from 12.1% (95% CI 11.9 to 12.2) in 1999 to 8.9% (95% CI 8.8 to 9.1) in 2010, a relative decline of 26.4%. The observed recurrent AMI hospitalization rate declined by a relative 27.7% in whites, from 11.9% (95% CI 11.8 to 12.1) to 8.6% (95% CI 8.5 to 8.8) versus a relative decline in blacks of 13.6% from 13.2% (95% CI 12.6 to 13.8) to 11.4% (95% CI 10.9 to 12.0). The risk‐adjusted rate of annual decline in recurrent AMI hospitalizations was 4.1% (HR 0.959; 95% CI 0.958 to 0.961), and whites experienced a higher rate of decline (HR 0.957, 95% CI 0.956 to 0.959) than blacks (HR 0.974, 95% CI 0.970 to 0.979).The overall, observed 1‐year mortality rate after hospitalization for recurrent AMI declined from 32.4% in 1999 to 29.7% in 2010, a relative decline of 8.3% (P<0.05). In adjusted analyses, 1‐year mortality after recurrent AMI hospitalization declined 1.8% per year (HR, 0.982; 95% CI 0.980 to 0.985). Conclusions In a national sample of Medicare beneficiaries hospitalized for AMI from 1999 to 2010, hospitalization for recurrent AMI decreased, as did subsequent mortality, albeit to a lesser extent. The risk of recurrent AMI hospitalization declined less in black patients than in whites, increasing observed racial disparities by the end of the study period.

[1]  N. Wong,et al.  Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010). , 2013, The American journal of cardiology.

[2]  D. Kolte,et al.  ST-elevation myocardial infarction in the elderly--temporal trends in incidence, utilization of percutaneous coronary intervention and outcomes in the United States. , 2013, International journal of cardiology.

[3]  S. Normand,et al.  Recent Declines in Hospitalizations for Acute Myocardial Infarction for Medicare Fee-for-Service Beneficiaries: Progress and Continuing Challenges , 2010, Circulation.

[4]  R. Goldberg,et al.  Disparities in Combination Drug Therapy Use in Older Adults with Coronary Heart Disease , 2010, Drugs & aging.

[5]  J. Gore,et al.  Contemporary trends in evidence-based treatment for acute myocardial infarction. , 2010, The American journal of medicine.

[6]  E. Braunwald,et al.  Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction , 2009, Journal of the American College of Cardiology.

[7]  H. Wedel,et al.  Hazard Function and Secular Trends in the Risk of Recurrent Acute Myocardial Infarction: 30 Years of Follow-Up of More Than 775 000 Incidents , 2009, Circulation. Cardiovascular quality and outcomes.

[8]  J. Murabito,et al.  Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction , 2008, Circulation.

[9]  Helen Y. Lee,et al.  Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge , 2008, Journal of managed care pharmacy : JMCP.

[10]  J. Gore,et al.  Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective. , 2007, Archives of internal medicine.

[11]  S. Normand,et al.  An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With an Acute Myocardial Infarction , 2006, Circulation.

[12]  L. Køber,et al.  Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002 , 2005, Heart.

[13]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[14]  J. Gore,et al.  Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. , 2005, American heart journal.

[15]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[16]  V. Gudnason,et al.  The absolute risk of recurrent myocardial infarction is similar amongst both sexes: MONICA Iceland Study 1981–1999 , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[17]  Harlan M Krumholz,et al.  National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. , 2003, Archives of internal medicine.

[18]  V. Salomaa,et al.  Trends in coronary events in Finland during 1983-1997. The FINAMI study. , 2003, European heart journal.

[19]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[20]  A. Folsom,et al.  Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. , 2001, International journal of epidemiology.

[21]  J. Gore,et al.  Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: A community-wide perspective. , 2001, American heart journal.

[22]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[23]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[24]  U. Goldbourt,et al.  Prognosis of patients with a recurrent acute myocardial infarction before and in the reperfusion era--a national study. , 2001, American heart journal.

[25]  W. Rogers,et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.

[26]  A. Folsom,et al.  Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. , 1998, The New England journal of medicine.

[27]  V. Salomaa,et al.  Decline of coronary heart disease mortality in Finland during 1983 to 1992: roles of incidence, recurrence, and case-fatality. The FINMONICA MI Register Study. , 1996, Circulation.

[28]  E. Peterson,et al.  Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. , 1994, JAMA.

[29]  W. Rogers,et al.  Race and Prognosis After Myocardial Infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial , 1993, Circulation.

[30]  C. Franklin,et al.  Survival rates and prehospital delay during myocardial infarction among black persons. , 1986, The American journal of cardiology.

[31]  R. Califf,et al.  Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. , 2006, The American journal of medicine.

[32]  M. Schroll,et al.  Trends in incidence, case-fatality and recurrence of myocardial infarction in the Danish MONICA population 1982–1991 , 2004, European Journal of Epidemiology.

[33]  Michael Miller Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[34]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .